TheraCell to launch a comprehensive portfolio of demineralized bone fiber solutions

August 6, 2019 – Los Angeles, CA — TheraCell, Inc., the inventor of the 2nd Generation TheraFuze DBF® demineralized bone fiber technology, announced today that it plans to launch a comprehensive portfolio of demineralized bone fiber solutions at this year’s North American Spine Society meeting being held September 25-28 in Chicago, IL.

This best in industry portfolio includes the broadest range of demineralized bone fiber solutions including 1, 2 and 3-level Fiber Boats and a novel Fiber Wrap™ as well as unique, patent protected procedure specific Fiber Bullets™ for minimally invasive surgery (MIS) and its much anticipated Fiber Anchor™ that has been shown to greatly improve screw fixation in osteoporotic bone and revision models.

All of these products are being manufactured exclusively for TheraCell by Pinnacle Tissue Transplant, Phoenix, AZ.

Visit us at NASS Booth 4234 to learn more about TheraCell’s TheraFuze DBF® technology, and its expansive family of products.


About TheraCell, Inc.
TheraCell is a leading developer of novel bone based osteobiologic solutions for musculoskeletal repair. Its 2nd generation ‘controlled geometry’ demineralized fiber technology represents a meaningful advance in more fully respecting the gift of tissue by efficiently and cost-effectively processing the tissue with high yields to produce a broad range of new solutions. Its core fiber and boat products are currently licensed to AlloSource, and sold by AlloSource and Nuvasive as well as to Australian Biotechnologies in Australia and New Zealand with over 10,000 implants delivered to date. TheraCell’s O2ssify™, oxygenation technology slated to be launched in 2020 is anticipated to offer a further meaningful advance in bone healing.

Patents: US 9,572,912; US 9,486,557; AUS 2014253753; and other patents pending.